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INTRODUCTION
Mutated EGFR and translocations in ALK are major drug tar-
gets in non-small cell lung cancer (NSCLC). In general, these two
oncogenic drivers exist exclusively (1). Here we present to the
best of our knowledge the first patient who had two simultaneous
lung cancers with EGFR mutation and ALK translocation in each
respective lesion, and was successfully treated with ALK inhibitor
alectinib at the post-surgical recurrence.
CASE REPORT
A 36-year-old male, who was 8-pack year current smoker with
no significant previous medical history, was found to have right
lung opacity on a chest radiograph during a health examination. A
computed tomography chest scan revealed two nodules in the right
lower lobe, a 2.6 cm lesion in S8/9 with a cavity and ground glass
opacity, and a solid and lobulated 2.1 cm lesion in S9. The maxi-
mum standard uptake value (SUVmax) of S8/9 and S9 lesions by
FDG-PET scan was 1.9 and 15.3, respectively (Fig. 1). No signifi-
cant accumulation was detected elsewhere. Each lesion was diag-
nosed as cT1bN0M0 (cStage IA) and a thoracoscopic right lower
lobectomy with mediastinal lymphadenectomy was performed.
Histological examination revealed the right S8/9 lesion to be inva-
sive adenocarcinoma primarily with a lepidic growth component
and the S9 lesion as invasive papillary adenocarcinoma with a mi-
cropapillary component. Mediastinal (#7, 4/6) and right hilar
lymph node (#11,1/6) metastases were detected.
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Figure 1. Radiographical appearance of the two lung lesions. (A)
Chest radiograph showing the opacity in the right lower field. (B)
Chest CT scan showing right lung lesions in S8/9. (C) Chest CT scan
showing right lung lesions in S9. (D) FDG-PET scan showing low
accumulation in the S8/9 lesion. (E) FDG-PET scan showing high
accumulation in the S9 lesion.
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An EGFR -L858R mutation was detected by PCR-Invader assay
in the S8/9, but not S9 lesion. FISH analyses for ALK and EML4
revealed that cells from the S9, but not S8/9 lesion, had an EML4-
ALK fusion (Fig. 2). Analysis with 5’ -RACE using corresponding
formalin- fixed paraffin-embedded tissue (2) further revealed the S9
tumor to have EML4-ALK E13 ; A20 (variant 1). Immunohisto-
chemistry with specific antibodies for L858R mutant EGFR, and
ALK showed that the S8/9, but not S9 lesion, was positive for
EGFR -L858R. The S9, but not S8/9 lesion, was positive for ALK
(Fig. 3), consistent with genetic results. Mediastinal and right hilar
lymph nodemetastases were positive for ALK, but not EGFR-L858R
(Fig. 3).
Therefore, we diagnosed that this patient had double lung can-
cers consisting of an EGFR -L858R mutation positivelesion (pT1bN0
M0, pStage IA) and an EML4-ALK translocation positive lesion
(pT2aN2M0, pStage IIIA). Treatment with adjuvant chemotherapy
consisting of 4 cycles of cisplatin and vinorelbin was given. Ten
months after the completion of the adjuvant chemotherapy, the
multiple bone metastases, associated with small volume of right
pleural effusion, pericardial effusion, and elevated level of serum
carcinoembryonic antigen (CEA), were detected by FDG-PET scan
(Fig. 4). Re-biopsy could not be performed because there were no
lesions for safe biopsy. We diagnosed the patient had recurrence of
EML4-ALK lung cancer component, since EML4-ALK positive
tumor cells invaded the mediastinal and right hilar lymph nodes.
The patient was treated with an ALK inhibitor alectinib (300 mg
twice a day)(3). FDG-PET and CT scan taken 3 months after the
initiation of alectinib revealed that accumulation in multiple bone
lesions, right pleural effusion, and pericardial effusion disappeared
(Fig. 4). Elevated level of CEA was improved with in normal limit by
the treatment. Alectinib treatment is continued for longer than 17
months.
Figure 2. Detection of EML4-ALK in tumor cells in the S9 lesion. (A)
FISH analyses for ALK and EML4 revealed tumor cells in the S9 lesion,
but not the S8/9 lesion, had an EML4-ALK fusion gene (5’ALK, red ;
3’ALK, green ; EML4, blue). Arrowheads indicate the rearranged EML4-
ALK allele. (B) Sequence of the junction between EML4 exon 13 and ALK
exon 20 in the S9 lesion, with an arrow indicating the junction.
Figure 3. Histological findings of the two lung lesions. H&E staining and immunohistochemistry with anti -L858R mutant EGFR specific
antibody and anti -ALK antibody of lung lesions (S8/9 and S9) and mediastinal lymphnode metastasis are shown (10objective).
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DISCUSSION
Three case reports (4-6) describe lung cancer patients with con-
comitant EGFRmutation and ALK translocation. However, it is un-
clear from these reports whether two tumors, each with one ge-
netic alteration developed simultaneously, or a single tumor ac-
quired both oncogenic drivers during its development. In our
case, it is clear that two different lesions with different oncogenic
drivers developed independently, because the microscopic appear-
ance (lepidic vs papillary) and oncogenic drivers (EGFRmutation
vs ALK translocation) were quite different in the surgically re-
sected two tumors. This further indicates that double cancers with
different oncogenic drivers can occur even in a young individual.
Recent clinical trials show the possibility of molecular diagnosis
utilizing liquid biopsy specimens. However, it is still challenging in
the clinical practice. Since our case did not have lesion for safere-
biopsy at the disease recurrence, we could not perform re-biopsy
for assessing EGFR mutation and ALK translocation. We alterna-
tively diagnosed that EML4-ALK component developed recurrent
disease, because EML4-ALK component metastasized mediastinal
and hiller lymph nodes at the surgical resection for double primary
tumors. As the result, recurrent disease was dramatically dimin-
ished by alectinib treatment and controlled longer than 17 months.
Our case also informed the importance of intensive molecular
pathological diagnosis of surgical specimens for precision medi-
cine by targeted drugs for recurrent disease.
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